Skip to main content

Table 1 Changes of clinical and biochemical parameters after treatment

From: Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease

 

BBR plus LSI (n = 41)

P value

LSI (n = 39)

P value

 

Baseline

After 16 w

Baseline

After 16 w

Sex (M/F)

26/15

  

20/19

  

Age (years)

51.2 ± 9.4

  

50.8 ± 10.4

  

Weight (kg)

77.0 ± 15.4

72.8 ± 13.3

<0.01

75.9 ± 10.6

74.0 ± 11.1

<0.05

BMI (kg/m2)

27.4 ± 4.1

25.5 ± 3.3

<0.01

27.3 ± 3.0

26.0 ± 5.9

<0.05

Waist (cm)

94.5 ± 11.1

89.7 ± 9.7

<0.01

93.1 ± 7.3

90.8 ± 8.5

<0.05

HFC (%)

30.3 (22.2–44.0)

13.6 (9.3–17.4)

<0.01

28.7 (21.9–46.8)

20.3 (11.3–33.0)

<0.05

Blood glucose (mmol/L)

 0 min

6.4 ± 0.9

6.1 ± 1.3

<0.01

6.2 ± 1.0

6.2 ± 0.9

0.47

 30 min

11.1 ± 1.7

9.9 ± 1.9

<0.05

11.0 ± 1.7

10.4 ± 2.1

0.13

 60 min

13.1 ± 2.5

11.1 ± 2.6

<0.05

13.0 ± 2.6

11.9 ± 3.1

<0.05

 120 min

11.2 ± 3.0

8.6 ± 2.8

<0.05

10.8 ± 3.3

10.1 ± 2.9

0.14

 180 min

7.2 ± 2.3

5.4 ± 1.6

<0.05

6.5 ± 2.8

5.9 ± 2.3

<0.05

 AUCg

42.4 ± 7.6

36.3 ± 8.4

<0.05

41.2 ± 8.4

39.1 ± 9.3

<0.05

 HbA1c (%)

6.4 ± 0.7

6.0 ± 0.4

<0.01

6.3 ± 0.7

6.2 ± 0.7

0.11

Serum insulin (mU/mL)

      

 0 min

13.4 (8.5–16.2)

10.8 (8.5–14.1)

0.97

3.4 (8.6–18.6)

12.4 (7.1–19.1)

0.89

 30 min

41.0 (30.6–62.2)

47.9 (33.3–88.5)

0.34

59.9 (33.2–83.4)

54.2 (28.8–77.7)

0.28

 120 min

69.9 (47.5–100.9)

68.0 (41.2–103.1)

0.75

78.1 (57.1–132.7)

74.6 (45.7–117.9)

0.23

 HOMA-IR

3.6 (2.4–4.1)

2.8 (2.2–3.9)

0.21

3.7 (2.5–5.0)

3.4 (1.8–5.1)

0.32

 HOMAβ

88.2 (54.3–114.4)

93.1 (64.1–129.6)

0.12

97.7 (62.2–151.1)

100.0 (56.8–152.6)

0.69

 ΔI30/ΔG30

8.0 (4.1–13.6)

10.7 (5.3–20.3)

P < 0.05

9.4 (5.0–16.6)

9.3 (3.6–18.6)

0.65

 TC (mmol/L)

5.3 ± 0.9

4.6 ± 1.0

P < 0.01

5.0 ± 0.8

5.0 ± 0.8

0.92

 TG (mmol/L)

2.2 ± 1.2

1.6 ± 0.9

P < 0.05

2.0 ± 0.8

1.9 ± 1.1

0.69

 HDL-c (mmol/L)

1.2 ± 0.2

1.2 ± 0.3

0.65

1.2 ± 0.3

1.2 ± 0.2

0.55

 LDL-c (mmol/L)

3.2 ± 0.9

3.0 ± 0.9

P < 0.05

3.0 ± 0.8

3.0 ± 0.8

0.73

 APO-A(g/L)

1.3 (1.1–1.4)

1.2 (1.0–1.3)

P < 0.05

1.3 (1.0–1.4)

1.3 (1.1–1.5)

0.89

 APO-B(g/L)

1.0 ± 0.2

0.9 ± 0.2

P < 0.05

1.0 ± 0.2

1.0 ± 0.2

0.28

 APO-E (mg/L)

48.0 (37.0–57.3)

42.5 (36.0–49.7)

0.08

44.0 (37.9–52.3)

44.0 (38.5–56.5)

0.94

 LP(a) (mg/L)

104.0 (50.0–248.0)

101.0 (49.5–272.0)

P < 0.05

155.0 (78.0–218.0)

160.0 (90.3–263.0)

0.23

Liver enzyme (U/L)

 ALT

36.0 (24.5–47.0)

21.0 (13.5–29.5)

P < 0.01

34.0 (25.3–46.5)

21.0 (15.0–36.3)

P < 0.01

 AST

25.0 (20.0–32.0)

19.0 (16.0–22.5)

P < 0.01

25.0 (20.0–30.0)

20.5 (15.8–27.0)

P < 0.05

 γ-GT

39.0 (26.0–67.5)

30.0 (23.0–43.0)

P < 0.01

33.0 (22.0–56.5)

27.5 (20.5–48.8)

P < 0.05

  1. The data were presented as the mean ± SD, except for skewed variables, which were presented as the median with the interquartile range given in parentheses
  2. LSI lifestyle intervention, BBR plus LSI berberine treatment plus lifestyle intervention, BMI body-mass index, HFC hepatic fat content, TC total cholesterol, TG triglyceride, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GT γ-glutamyltransferase